Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-3R is a research peptide sold for laboratory use only — it is not intended for human consumption. These statements have not been evaluated by the FDA. Always consult your healthcare provider before making decisions about any research compounds.
What Sourced Peptides' GLP-3R Actually Is—And What It Isn't
Sourced Peptides markets a research peptide called GLP-3R that mirrors the structure of retatrutide (LY3437943), a triple-receptor agonist currently undergoing Phase 3 clinical trials at Eli Lilly. Tutela Medical must establish this distinction immediately: GLP-3R is a commercial research chemical, not an FDA-approved pharmaceutical. The clinical efficacy data cited below derives from Eli Lilly's controlled trials of their proprietary formulation—not from testing of Sourced Peptides' product on human subjects. This is a critical limitation that many vendors deliberately obscure. Tutela Medical does not obscure it.
The Three-Receptor Strategy: Why This Peptide Differs From Ozempic and Mounjaro
Understanding GLP-3R requires context. Semaglutide (Ozempic, Wegovy) activates one receptor: the GLP-1 receptor. Tirzepatide (Zepbound, Mounjaro) activates two: GLP-1R and GIPR (glucose-dependent insulinotropic polypeptide receptor). Retatrutide—the compound that GLP-3R is modeled after—targets three receptors simultaneously: GLP-1R, GIPR, and GCGR (glucagon receptor).
Theoretically, this triple agonism could amplify metabolic effects. Animal and cell-based research suggests that GCGR activation may enhance hepatic glucose output suppression and potentially increase energy expenditure—mechanisms not present in single- or dual-receptor agonists. However, Tutela Medical emphasizes the word “theoretically.” Sourced Peptides has not published peer-reviewed human trials of their GLP-3R product. The efficacy claims rest entirely on Eli Lilly's retatrutide data.
Clinical Data From Eli Lilly's Trials: The Context You Need
Eli Lilly's TRIUMPH-1 trial demonstrated that retatrutide produced approximately 28–30% body weight reduction over 68–80 weeks in obese adults. Semaglutide achieves roughly 15% reduction; tirzepatide around 22%. On paper, this triple agonist appears substantially more potent.
But critical nuance exists. These trials enrolled different patient populations with different baseline weights, durations, and dose escalation schedules. Direct head-to-head comparisons are limited. Moreover, Phase 3 is not final approval—adverse event profiles, long-term safety, and real-world efficacy remain under investigation. The FDA has not yet approved retatrutide as a pharmaceutical. Sourced Peptides' GLP-3R is a research peptide, not the product under FDA evaluation. Bioequivalence between a commercial research chemical and Eli Lilly's pharmaceutical-grade formulation is not guaranteed and has not been demonstrated.
Purity, Stability, and the Research-Grade Supply Chain
Sourced Peptides specifies that their GLP-3R carries ≥99% HPLC purity and includes batch-specific Certificates of Analysis. Third-party lab testing is noted as part of their quality assurance. The product arrives as a lyophilized (freeze-dried) powder, stable at room temperature between 15–25°C.
These specifications suggest attention to chemical stability and identity verification. However, Tutela Medical observes that “research grade” supply chains operate outside FDA GMP (Good Manufacturing Practice) oversight. Purity verification via HPLC confirms chemical identity and concentration, but does not assess bioavailability, sterility, endotoxin load, or stability under varied storage conditions that real-world consumers may encounter. A Certificate of Analysis from an independent third-party lab is preferable to none, but does not carry the regulatory weight of pharmaceutical-grade certification.
Adverse Events Documented in Eli Lilly's Retatrutide Trials
Sourced Peptides' product page does not make health or safety claims, which is appropriate for a research-only peptide. However, Tutela Medical flags the known side effect profile from Eli Lilly's clinical trials, since researchers and institutional review boards will want this baseline data:
- Gastrointestinal effects (nausea, vomiting) occurred in approximately 25–30% of trial participants
- Paresthesia (skin tingling and numbness sensations) was reported
- Elevated resting heart rate was observed in some subjects
The mechanism underlying GI tolerability—whether it improves or worsens relative to dual agonists—remains incompletely characterized. Long-term safety data at doses approaching the triple-agonist ceiling are still being collected. Any researcher or laboratory considering this peptide must acknowledge that safety extrapolation from Eli Lilly's controlled population to other contexts carries substantial uncertainty.
Pricing Opacity and the Red Flag of “Research Only” Markets
Sourced Peptides does not display pricing on their product page, requiring visitors to contact the vendor directly. Tutela Medical notes this as a minor transparency gap. More concerning is the broader ecosystem: research peptides marketed without pricing transparency often occupy a gray zone. Vendors may position products as “research only” to sidestep FDA jurisdiction, while tacitly understanding or encouraging human use.
GLP-3R is not approved for human consumption under any regulatory framework. It is not a pharmaceutical. Clinical trials of the analogous compound (Eli Lilly's retatrutide) are ongoing; the FDA may approve a pharmaceutical version around 2027, if trials succeed. Until then, any human use of Sourced Peptides' GLP-3R would be off-label, unregulated, and unsupervised—a scenario laden with medical and legal risk.
Bottom Line: Research Potential Versus Regulatory Reality
Sourced Peptides' GLP-3R represents a triple-receptor agonist peptide with chemical purity verification and theoretical potency that exceeds available single- and dual-receptor competitors. The underlying biology is plausible; the Eli Lilly clinical data is compelling within its scope. The vendor has not made overt health claims and specifies research-only positioning, which Tutela Medical credits as responsible messaging.
However, this is a research chemical, not a therapeutic. No human safety or efficacy data exist for Sourced Peptides' specific formulation. Researchers or institutions considering this peptide should recognize the gap between promising Phase 3 data and regulatory approval—a gap measured in years and contingent on ongoing trials. The adverse event profile is non-trivial. Pricing is opaque. And the regulatory pathway to human therapeutic use remains incomplete.
Tutela Medical's assessment: GLP-3R merits interest from legitimate research contexts and institutional labs with appropriate ethical oversight. For any other use, it remains a speculative research compound with significant unknowns.
Compare Other GLP-3R Triple-Agonist Vendors
This review is part of our ongoing evaluation of research-grade retatrutide (GLP-3R) vendors. For a complete picture, see how other suppliers compare:
- the Amino Asylum retatrutide evaluation — Finnrick-rated 78% (#2 of 223 vendors) with mixed dosage results but consistent purity
- Swole AF Labs transparency analysis — UK-based vendor with no Finnrick-verified independent testing on record — transparency gaps noted
- Peptide Sciences vendor evaluation — 41 independent tests on record but only 51% pass rate — the most-tested vendor with inconsistent results
- Nationwide Peptides purity evaluation — Claims ≥99% purity with COA (HPLC/MS) and GMP synthesis — not yet Finnrick-verified
Each vendor review examines purity testing, dosage accuracy, pricing, and transparency — the factors that matter most for research-grade peptide procurement.
These statements have not been evaluated by the FDA. GLP-3R is a research peptide not intended for human consumption. Always consult a qualified healthcare provider before considering any research compounds.